SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Art Pappas to participate on panel, "Investing in Neurotech" at Neurotech Investing and Partnering Conference in Boston, MA
News | 05. 19. 2010
